Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: Outcome of hepatorenal transplantation

Adam G. Testro, Stephen O. Brennan, Richard A.L. Macdonell, Philip N. Hawkins, Peter W. Angus – 28 June 2007 – Liver transplantation (LT) has been reported in only 1 patient with hereditary variant apolipoprotein AI (apoAI) amyloidosis and was associated with a 50% decrease in production of variant apoAI. The potential for this to benefit clinical manifestations of apoAI amyloidosis such as peripheral neuropathy has not been determined.

Recurrent hepatocellular carcinoma is a problem we need to tackle

James D. Perkins – 28 June 2007 – Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post‐OLT antirecurrence efficacy of Licartin in advanced HCC patients.

Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B

Fiona Fernandes, Daniel S. Poole, Spencer Hoover, Rannveig Middleton, Adin‐Cristian Andrei, Justin Gerstner, Rob Striker – 28 June 2007 – HCV reoccurs after liver transplantation and increases mortality. Cyclosporine, but not tacrolimus, has potent antiviral effects against HCV replication in cell culture. To determine the conditions, if any, under which HCV is susceptible to cyclosporine in vivo, we selected for cyclosporine‐resistant mutant HCV in vitro. The resulting mutations were mapped to x‐ray crystallographic structures and sequence databases.

Subscribe to